Last updated on March 2020

A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension


Brief description of study

This study will evaluate the efficacy, safety, and pharmacokinetics of 10 mg of oral administration balovaptan once a day (QD) compared with matching placebo in adults (18 years and older) with autism spectrum disorder (ASD).

Clinical Study Identifier: NCT03504917

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.